Update shared on07 Aug 2025
Fair value Increased 14%Despite a modest decline in consensus revenue growth forecasts and a slight increase in the discount rate, the consensus analyst price target for Adaptive Biotechnologies has been raised from $11.86 to $13.29.
What's in the News
- Raised full year 2025 MRD business revenue guidance to $190–200 million from the prior $180–190 million range; no revenue guidance for Immune Medicine.
- Integrated clonoSEQ MRD test into Flatiron Health’s OncoEMR platform, expanding streamlined access to 4,500 clinicians across 1,000 U.S. community cancer locations.
- Rebalanced in key indices: added to Russell 2000/2500/3000 Growth and Microcap Growth benchmarks, and dropped from corresponding Value indices.
- clonoSEQ MRD test featured in 30 presentations, including 14 oral, at ASCO and EHA conferences, highlighting usage in B-cell acute lymphoblastic leukemia and multiple myeloma studies.
Valuation Changes
Summary of Valuation Changes for Adaptive Biotechnologies
- The Consensus Analyst Price Target has significantly risen from $11.86 to $13.29.
- The Consensus Revenue Growth forecasts for Adaptive Biotechnologies has fallen slightly from 21.3% per annum to 20.2% per annum.
- The Discount Rate for Adaptive Biotechnologies has risen slightly from 7.05% to 7.37%.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.